Home › Funds › Aristotle Atlantic Partners, LLC › ADPT

Aristotle Atlantic Partners, LLC position in ADPT

ADAPTIVE BIOTECHNOLOGIES COR · Health Care

Aristotle Atlantic Partners, LLC reported holding 1,838,513 shares of ADPT (ADAPTIVE BIOTECHNOLOGIES COR) in its Q2 2026 13F filing — a position valued at US$39.4M, representing 1.64% of its reported portfolio and ranking #17 among its reported holdings. Aristotle Atlantic Partners, LLC has disclosed ADPT holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)1.84M sh
Reported value held$39.44M
Portfolio Weight1.64%
First reportedQ3 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Aristotle Atlantic Partners, LLC's ADPT position evolved

Aristotle Atlantic Partners, LLC first disclosed a stake in ADPT in Q3 2023 at 3,058,206 shares (US$16.7M). The position peaked in Q3 2025 at 3,126,719 shares, worth US$46.8M. Across 12 filings, Aristotle Atlantic Partners, LLC increased the stake 4 time(s), trimmed it 6 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 1,838,513 shares valued at US$39.4M — an increase of 124,167 shares quarter over quarter.. Notable position changes include a 41% trim in Q4 2025 (shares fell 15% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 3.06M $16.67M New
Q4 2023 3.05M $14.95M Hold
Q1 2024 2.99M $9.61M Reduce
Q2 2024 2.97M $10.77M Reduce
Q3 2024 3.00M $15.37M Add
Q4 2024 2.89M $17.31M Reduce
Q1 2025 2.94M $21.85M Add
Q2 2025 2.88M $33.54M Reduce
Q3 2025 3.13M $46.78M Add
Q4 2025 1.84M $29.92M Reduce
Q1 2026 1.71M $23.80M Reduce
Q2 2026 1.84M $39.44M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ADPT and 13F data

ADPT (ADAPTIVE BIOTECHNOLOGIES COR) is a Health Care company. 52 other funds we track also report a position in ADPT — the largest reported positions include Viking Global Investors (US$643.4M), VIKING GLOBAL INVESTORS LP (US$643.4M), PERCEPTIVE ADVISORS LLC (US$26.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ADPT

All ADPT fund holders →

FAQ

How long has Aristotle Atlantic Partners, LLC held ADPT?

Aristotle Atlantic Partners, LLC has disclosed ADPT holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Aristotle Atlantic Partners, LLC's current position in ADPT?

As of Q2 2026, Aristotle Atlantic Partners, LLC holds 1.84M shares of ADPT (ADAPTIVE BIOTECHNOLOGIES COR), valued at $39.44M, representing 1.64% of its reported portfolio and ranking #17.

Has Aristotle Atlantic Partners, LLC been buying or selling ADPT?

In the latest 13F filing (Q2 2026), Aristotle Atlantic Partners, LLC increased its position in ADPT. The position peaked in Q3 2025 at 3.13M shares.

Which other funds hold ADPT?

Other major institutional holders of ADPT include Viking Global Investors, VIKING GLOBAL INVESTORS LP, PERCEPTIVE ADVISORS LLC, among 52 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.